Skip to content


Volume 16 Supplement 1

1st Joint ANIRCEF-SISC Congress

  • Invited speaker presentation
  • Open Access

Migraine during perimenopause

  • 1Email author,
  • 1,
  • 1 and
  • 1
The Journal of Headache and Pain201516 (Suppl 1) :A25

  • Published:


  • Migraine
  • Hormone Replacement Therapy
  • Migraine With Aura
  • Tibolone
  • Premenstrual Syndrome

Migraine affects the female sex to a greater extent than the male, with a female:male ratio of 3:1. Hormonal fluctuations during the reproductive life may influence migraine occurrence and intensity, both in a positive or negative way. Many women experience migraine approaching menopause, but the trend of migraine symptoms may vary according to the different stages of the perimenopause. If a woman is already a migraineur subject, the attacks often worsen during both the early and late phases of menopausal transition, whereas an onset of migraine is quite rare[1]. According to some authors, women with premenstrual syndrome (PMS) before menopause have an increased prevalence of migraine in late menopausal transition, and a subsequent reduction of the attacks in postmenopause[2]. The presence of PMS can be considered one of the predictors of migraine trend during the menopausal transition, since women with PMS are more sensitive to hormonal fluctuations and more prone to develop moderate to severe menopausal symptoms[3]. Hormone replacement therapy (HRT) can be used during the late premenopausal phase and the first years of postmenopause in order to counteract climacteric symptoms[4]. The effect of HRT on migraine has been investigated, either in its role of provoking or preventing the attacks. HRT should be administered continuously, without intervals, to avoid sudden estrogen deprivation and the consequent possible onset of migraine[5]. Treatment with estradiol-based gels and transdermal patches is preferable to oral formulation as it maintains constant serum hormone levels. In contrast to guidelines on the use of estroprogestinic contraceptives, migraine with aura is not an absolute contraindication to HRT when the way of administration is topical with a low dose of natural estrogens. If the aura recurs or worsens, HRT should be in any case discontinued[6]. When the effect of tibolone versus continuous combined HRT regimen in migraine is compared, a significant reduction in the hours with pain-limiting daily activities and of the amount of analgesics intake can be observed, even if there is no reduction of the days with migraine[7]. Natural menopause is associated with a lower incidence of migraine as compared with surgical menopause[8]; data on migraine prevalence in relation to the type of surgical procedure are till now unclear and contradictory[9].

Conflict of interest

None to declare.

Authors’ Affiliations

Department of Surgical Sciences, Women's Headache Center, University of Turin, Turin, Italy


  1. Allais G, Chiarle G, Bergandi F, Benedetto C: Migraine in perimenopausal women. Neurol Sci. 2015, 36 (Suppl 1): S79-S83.View ArticleGoogle Scholar
  2. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH: Migraine prevalence during menopausal transition. Headache. 2003, 43: 470-478. 10.1046/j.1526-4610.2003.03092.x.View ArticlePubMedGoogle Scholar
  3. Freeman EW, Sammuel MD, Lin H, Gracia CR, Kapoor S: Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol. 2008, 111: 127-136. 10.1097/01.AOG.0000295867.06184.b1.View ArticlePubMedGoogle Scholar
  4. MacGregor EA: Effects of oral and transdermal estrogen replacement on migraine. Cephalalgia. 1999, 19: 124-5. 10.1046/j.1468-2982.1999.019002124.x.View ArticlePubMedGoogle Scholar
  5. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A: Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006, 67: 2159-2163. 10.1212/01.wnl.0000249114.52802.55.View ArticlePubMedGoogle Scholar
  6. MacGregor EA: Perimenopausal migraine in women with vasomotor symptoms. Maturitas. 2012, 71: 79-82. 10.1016/j.maturitas.2011.11.001.View ArticlePubMedGoogle Scholar
  7. Nappi RE, Sances G, Sommacal A, et al: Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause. 2006, 13: 818-825. 10.1097/01.gme.0000227399.53192.f5.View ArticlePubMedGoogle Scholar
  8. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993, 17: 31-37. 10.1016/0378-5122(93)90121-W.View ArticlePubMedGoogle Scholar
  9. Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA: Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol. 1993, 168 (3 Pt 1): 765-771.View ArticlePubMedGoogle Scholar


© Allais et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.